查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
2018631

伴侣动物术后疼痛管理治疗市场：依产品种类、动物种类、给药途径及最终使用者划分－2026年至2032年全球市场预测

Companion Animal Postoperative Pain Management Therapeutics Market by Product Type, Animal Type, Route Of Administration, End User - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 181 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

2025 年，伴侣动物术后疼痛管理疗法的市值为 1.6465 亿美元，预计到 2026 年将增长至 1.8638 亿美元，复合年增长率为 10.36%，到 ​​2032 年将达到 3.2845 亿美元。

主要市场统计数据
基准年 2025 1.6465亿美元
预计年份：2026年 1.8638亿美元
预测年份 2032 3.2845亿美元
复合年增长率 (%) 10.36%

对影响伴侣动物术后疼痛管理的临床、技术和商业性发展趋势进行了权威概述。

伴侣动物术后疼痛管理已从单一的临床问题发展成为一项涵盖药理学、手术方案设计和饲主教育的多学科挑战。临床医生如今需要在疗效、安全性和饲主依从性之间取得平衡，同时还要应对日益严格的阿片类药物使用监管和不断涌现的替代疗法选择。因此，治疗决策不仅要考虑犬猫的急性疼痛缓解需求，还要兼顾长期福利、诊所的财务状况以及供应链的实际情况。

临床方案的演变、製剂的突破性进展以及分销管道的变化如何重新定义伴侣动物的术后疼痛管理。

伴侣动物术后疼痛管理领域正经历一场变革，这得益于临床实务、技术和经销领域多项创新成果的融合。临床上，多因子镇痛方案正被加速采用，这些方案结合了局部麻醉剂、非类固醇消炎剂和选择性鸦片类药物，旨在优化疼痛管理并最大限度地减少副作用。这一转变体现了人们对疼痛病理生理学的更深入理解，以及向循证、个体化的围手术全期计划迈进的趋势。

2025 年关税措施对伴侣动物镇痛药的采购、定价结构和库存策略的综合影响。

2025年起实施的累积关税为兽药相关人员的供应链和成本管理带来了新的复杂性。关税带来的成本压力迫使生产商和经销商重新评估筹资策略，优先考虑区域供应稳定，并尽可能考虑将特定生产流程转移到国内或近岸地区。因此，采购团队越来越注重供应商多元化，以降低供应来源集中和关税波动带来的风险。

差异化細項分析揭示了产品类型、动物种类、给药途径和分销管道结构如何独特地影响临床应用和商业策略。

对术后镇痛生态系统的详细细分和分析揭示了临床应用、製剂偏好和分销管道趋势方面的显着差异，这些差异正在推动差异化的商业策略。就产品类型而言，该领域主要围绕局部麻醉剂、非类固醇消炎剂（ NSAIDs）和鸦片类药物展开，每种药物都具有独特的治疗作用和监管考虑。在局部麻醉剂中，Bupivacaine和Lidocaine等药物用于术中和术后即刻镇痛，缓释製剂的进步进一步提升了它们的战略价值。包括卡洛芬、德拉考昔、非罗考昔和美洛昔康在内的非类固醇非类固醇消炎剂是术后疼痛和发炎管理的核心，儘管它们的安全性和给药方法有所不同。Buprenornhine、Fentanyl和曲马多等鸦片类药物在中重度疼痛治疗中仍然发挥着重要作用，但它们面临着日益严格的管理框架，这影响着处方行为。

各地区在法规、临床实践和分销管道成熟度方面的差异，决定了每个全球市场进入、商业化和生命週期策略的差异化。

区域趋势对法规环境、流通结构和临床实践规范有着显着影响，从而在美洲、欧洲、中东、非洲和亚太地区创造了不同的机会。在美洲，完善的兽医基础设施和宠物饲主较高的消费水准促进了先进配方和综合围手术全期方案的快速普及，但报销模式仍以自费为主，因此对产品价值的感知更为敏感。在这种环境下，透过便利性、安全性以及能够引起临床医生和饲主共鸣的显着疗效来实现差异化，将具有显着优势。

现有製药公司、专业创新者和策略伙伴如何合作，以推动术后镇痛领域的临床引入、分销管道的拓展和产品差异化？

伴侣动物术后镇痛领域的竞争格局呈现出多元化的特点，既有成熟的製药公司，也有专注于兽药创新和製剂及给药方式创新的新兴生物製药公司。成熟公司凭藉其广泛的分销网络和与临床医生的良好关係，在医院和零售通路中保持着稳固的地位。同时，专业公司则透过突破性的缓释技术、经皮吸收系统以及简化手术全期工作流程的产品支援服务，在竞争中脱颖而出。

为了获得竞争优势，製药公司和经销商需要采取切实可行的策略措施，以协调证据产生、配方设计、供应弹性和通路整合。

产业领导企业应采取一致且以证据主导的策略，将产品创新与临床方案和通路实际情况结合，以确保永续的竞争优势。其中，应优先创建多模态临床证据，以证明局部麻醉剂、非类固醇抗发炎药和选择性鸦片类药物的联合应用如何改善患者预后并降低併发症率。基于真实世界环境的高品质临床试验以及真实世界数据的收集，不仅能够增强医院和诊所的价值提案，还能支持负责任的药物管理理念。

采用稳健的混合方法研究途径，结合临床医生访谈、文献整合和基于细分的场景分析，以检验对该行业的见解。

本执行摘要所依据的研究结合了多种定性和定量方法，旨在全面了解临床、商业和监管趋势。主要研究包括对兽医、全科医生、处方集管理人员和分销主管进行结构化访谈，以了解临床实践中的处方行为、分销管道偏好和营运限制。次要研究广泛涵盖了同行评审的兽医临床文献、监管指导文件以及公开的製剂和药物安全监测报告，以阐明产品层面的考虑因素和安全性概况。

本文简明扼要地整合了临床创新、监管预期和商业性实施，概述了未来的策略重点。

伴侣动物术后疼痛管理正处于转折点，临床最佳实践、製剂技术的进步以及不断发展的销售管道相互交汇，为相关人员创造了新的机会和责任。朝向多面向镇痛的转变，以及缓释局部麻醉剂和经皮製剂系统的创新，增强了提供有效且便于饲主的疼痛管理的能力。同时，监管机构对合理使用鸦片类药物的重视以及不断变化的定价结构，要求采用更完善的供应链和临床管治方法。

目录

第一章：序言

第二章：调查方法

  • 调查设计
  • 研究框架
  • 市场规模预测
  • 数据三角测量
  • 调查结果
  • 调查的前提
  • 研究限制

第三章执行摘要

  • 首席体验长观点
  • 市场规模和成长趋势
  • 2025年市占率分析
  • FPNV定位矩阵，2025
  • 新的商机
  • 下一代经营模式
  • 产业蓝图

第四章 市场概览

  • 产业生态系与价值链分析
  • 波特五力分析
  • PESTEL 分析
  • 市场展望
  • 上市策略

第五章 市场洞察

  • 消费者洞察与终端用户观点
  • 消费者体验基准
  • 机会映射
  • 分销通路分析
  • 价格趋势分析
  • 监理合规和标准框架
  • ESG与永续性分析
  • 中断和风险情景
  • 投资报酬率和成本效益分析

第六章：美国关税的累积影响，2025年

第七章：人工智慧的累积影响，2025年

第八章 伴侣动物术后疼痛管理治疗市场：依产品类型划分

  • 局部麻醉剂
    • Bupivacaine
    • Lidocaine
  • 非类固醇消炎剂
    • 卡洛芬
    • 德拉考昔
    • 菲洛昔布
    • 美洛昔康
  • 阿片类药物
    • Buprenornhine
    • Fentanyl
    • 特拉马多尔

第九章 伴侣动物术后疼痛管理治疗市场：依动物类型划分

  • 猫
  • 狗

第十章：伴侣动物术后疼痛管理治疗市场：依给药途径划分

  • 注射药物
  • 口服
  • 外用
  • 经皮吸收贴片

第十一章 伴侣动物术后疼痛管理治疗市场：依最终使用者划分

  • 网路药房
  • 兽医医院和诊所
    • 一般诊所
    • 专科医院
  • 兽用零售药房
    • 连锁药局
    • 独立经营药房

第十二章 伴侣动物术后疼痛管理治疗市场：依地区划分

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 欧洲、中东和非洲
    • 欧洲
    • 中东
    • 非洲
  • 亚太地区

第十三章 伴侣动物术后疼痛管理治疗市场：依组别划分

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第十四章 伴侣动物术后疼痛管理治疗市场：依国家划分

  • 我们
  • 加拿大
  • 墨西哥
  • 巴西
  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国

第十五章：美国伴侣动物术后疼痛管理治疗市场

第十六章：中国伴侣动物术后止痛治疗市场

第十七章 竞争格局

  • 市场集中度分析，2025年
    • 浓度比（CR）
    • 赫芬达尔-赫希曼指数 (HHI)
  • 近期趋势及影响分析，2025 年
  • 2025年产品系列分析
  • 基准分析，2025 年
  • Addison Biological Laboratory Inc.
  • Assisi Animal Health
  • Avazzia
  • Bayer AG
  • Bimeda Animal Health
  • Boehringer Ingelheim International GmbH
  • Cadila Healthcare Ltd.
  • Ceva Sante Animale
  • Chanelle Pharma Group
  • Daiichi Sankyo Co. Ltd.
  • Dechra Pharmaceuticals PLC
  • Elanco Animal Health Incorporated
  • Eltech K-Laser SRL
  • Fidelis Pharmaceuticals, LLC
  • Merck & Co.
  • Multi Radiance Medical
  • Norbrook Laboratories
  • Richter Pharma AG
  • SAVA Vet
  • Sequent Scientific Ltd.
  • VETINDIA Pharmaceuticals Limited
  • Vetoquinol SA
  • Virbac Group
  • Virpax Pharmaceuticals Inc.
  • Zoetis Inc.
Product Code: MRR-221461476CB6

The Companion Animal Postoperative Pain Management Therapeutics Market was valued at USD 164.65 million in 2025 and is projected to grow to USD 186.38 million in 2026, with a CAGR of 10.36%, reaching USD 328.45 million by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 164.65 million
Estimated Year [2026] USD 186.38 million
Forecast Year [2032] USD 328.45 million
CAGR (%) 10.36%

An authoritative orientation to the evolving clinical, technological, and commercial dynamics shaping postoperative pain therapies for companion animals

Companion animal postoperative pain management has evolved from a narrow clinical concern into a multidisciplinary imperative that spans pharmacology, surgical protocol design, and client education. Clinicians now balance efficacy, safety, and owner compliance while navigating heightened regulatory scrutiny around opioid use and a growing portfolio of alternatives. Consequently, therapeutic decision-making reflects not only the acute analgesic needs of cats and dogs but also longer-term welfare considerations, practice economics, and supply chain realities.

In parallel, advances in formulation technologies, such as extended-release local anesthetics and transdermal systems, are changing perioperative workflows and enabling more predictable analgesia with fewer administrations. These technical developments intersect with evolving practice settings; specialty hospitals, growing online pharmacy channels, and multi-site veterinary groups shape how products are prescribed, dispensed, and monitored. Therefore, stakeholders must synthesize clinical evidence, route-of-administration preferences, and end-user behaviors to design commercially viable and clinically effective strategies.

This report executive summary situates these dynamics within the broader therapeutic landscape for postoperative pain in cats and dogs, highlighting the clinical drivers, product innovation trajectories, and structural industry shifts that influence adoption. The aim is to equip decision-makers with an integrated perspective that supports tactical planning across R&D, regulatory engagement, and commercial execution.

How clinical protocol evolution, formulation breakthroughs, and shifting distribution channels are redefining postoperative pain management for companion animals

The landscape of postoperative pain management in companion animals is undergoing transformative shifts driven by converging clinical, technological, and distribution innovations. Clinically, there is an accelerating adoption of multimodal analgesia protocols that combine local anesthetics, non-steroidal anti-inflammatory drugs, and selective opioid use to optimize pain control while mitigating side effects. This shift represents a more nuanced appreciation of pain pathophysiology and a move toward individualized perioperative plans anchored in evidence-based practice.

Technologically, formulation science is delivering longer-acting local anesthetics and improved transdermal and injectable delivery systems, which reduce dosing frequency and improve owner adherence. These advances enable smoother transitions from hospital to home care and open opportunities for novel product positioning centered on convenience and sustained efficacy. Simultaneously, safety-focused innovation in NSAID chemistry and labeling, combined with better clinician education, is reducing adverse-event concerns that historically limited aggressive postoperative management.

On the commercial side, distribution and access are changing as online pharmacies gain traction alongside traditional veterinary hospitals and retail pharmacies. This diversification of channels compels manufacturers to adopt more sophisticated supply chain and pricing strategies. In addition, regulatory trends emphasizing opioid stewardship and post-market pharmacovigilance are reshaping product lifecycle planning. Taken together, these shifts create a more complex but opportunity-rich environment where clinical credibility, formulation differentiation, and channel-aligned commercialization determine success.

The compound effects of 2025 tariff measures on pharmaceutical sourcing, pricing architecture, and inventory strategies for companion animal analgesics

The introduction of cumulative tariffs in 2025 has added a new layer of complexity to supply chains and cost management for veterinary pharmaceutical stakeholders. Tariff-driven cost pressures have prompted manufacturers and distributors to reevaluate sourcing strategies, prioritize regional supply security, and consider onshoring or nearshoring certain manufacturing steps where feasible. As a result, procurement teams are increasingly focused on supplier diversification to reduce exposure to concentrated origin risks and tariff volatility.

These tariff effects propagate beyond direct input costs; they influence pricing negotiations with end-user channels, inventory management practices, and the structure of contractual agreements. Veterinary hospitals and clinics, especially smaller general practices, have had to reassess purchasing cadence and inventory buffers to mitigate price fluctuations. Meanwhile, chain pharmacies and larger specialty hospitals possess greater leverage to negotiate volume-based arrangements that can partially offset tariff-related cost increases.

Moreover, the tariff environment has accelerated conversations about formulation simplification and longer-dated products to rationalize logistics expenses. Transitional strategies include prioritizing products with durable shelf life, increasing the use of extended-release formulations to reduce reorder frequency, and aligning clinical protocols to favor therapies that balance administration complexity with supply resilience. Ultimately, tariff dynamics in 2025 have underscored the need for integrated commercial and supply-chain planning to maintain access and affordability for postoperative pain therapies in companion animals.

A differentiated segmentation analysis revealing how product types, animal species, administration routes, and channel structures uniquely shape clinical adoption and commercial strategy

A granular segmentation view of the postoperative analgesia ecosystem reveals critical variances in clinical use, formulation preference, and channel dynamics that drive differentiated commercial strategies. When considering product type, the field is structured around local anesthetics, non-steroidal anti-inflammatory drugs, and opioids, each with distinct therapeutic roles and regulatory considerations. Within local anesthetics, agents such as bupivacaine and lidocaine address intraoperative and immediate postoperative pain control, and advances in extended-release formulations magnify their strategic value. Non-steroidal anti-inflammatory drugs encompass molecules including carprofen, deracoxib, firocoxib, and meloxicam, which form the backbone of postoperative pain and inflammation management with varying safety profiles and dosing paradigms. Opioids such as buprenorphine, fentanyl, and tramadol maintain a role for moderate to severe pain but face increasingly stringent stewardship frameworks that influence prescribing behavior.

Animal type further stratifies clinical pathways, as cats and dogs exhibit important pharmacologic and behavioral differences that affect agent selection, dosing, and owner instructions. Cats, for instance, require particular attention to certain NSAID tolerability and opioid choice, while dogs benefit from a broader array of approved NSAID options and established perioperative pathways. Route of administration exerts a powerful influence on adoption and compliance; injectable formulations are favored for perioperative control in hospital settings, oral agents support home-based continuation of therapy, topical options address localized pain with lower systemic exposure, and transdermal patches offer extended analgesia suited to outpatient care and owner convenience.

End-user segmentation shapes access, prescribing patterns, and point-of-sale dynamics. Online pharmacies expand reach and convenience but bring considerations around regulatory compliance and clinician engagement. Veterinary hospitals and clinics, including general practices and specialty hospitals, serve as primary decision points for perioperative planning and on-site administration, while veterinary retail pharmacies-both chain and independent-play a critical role in dispensing and counseling at the point of release. These layered segmentation dimensions inform R&D prioritization, commercial targeting, and educational outreach, ensuring that product positioning aligns with the clinical realities and logistical preferences of each stakeholder group.

Regional variations in regulation, clinical practices, and channel maturity that dictate differentiated entry, commercialization, and lifecycle strategies across global markets

Regional dynamics materially influence regulatory environments, distribution architectures, and clinical practice norms, creating divergent opportunity sets across the Americas, Europe Middle East and Africa, and Asia-Pacific. In the Americas, established veterinary practice infrastructures and high pet-owner spend support rapid uptake of advanced formulations and comprehensive perioperative protocols, while reimbursement models remain largely private-pay and therefore sensitive to perceived value. This environment favors differentiation through convenience, proven safety, and demonstrable outcomes that resonate with clinicians and owners alike.

Across Europe, the Middle East and Africa, regulatory heterogeneity and varying market maturity produce a patchwork of adoption rates. Western European markets often mirror advanced clinical protocols and prioritize pharmacovigilance and labeling harmonization, whereas some markets in the broader region emphasize cost containment and incremental introductions of novel therapies. Regulatory frameworks that emphasize veterinary drug safety and antimicrobial stewardship also shape opioid access and NSAID labeling, influencing product rollouts and educational priorities.

Asia-Pacific presents a mix of fast-evolving companion animal care standards, significant investment in specialty veterinary services, and a rapidly expanding online pharmacy footprint. Certain countries in the region are accelerating clinical guideline adoption and are highly receptive to formulation innovations that reduce dosing frequency and support outpatient care. However, supply-chain complexity and local regulatory idiosyncrasies require targeted market-entry strategies that account for registration timelines, import requirements, and channel partner selection. Navigating these regional nuances is essential for aligning clinical evidence packages and commercialization plans with local expectations and constraints.

How incumbent manufacturers, specialty innovators, and strategic partners converge to drive clinical adoption, channel access, and product differentiation in postoperative analgesia

Competitive dynamics in the companion animal postoperative pain therapeutic area are characterized by a mix of established pharmaceutical manufacturers, specialty veterinary pharma innovators, and emerging biopharmaceutical entrants focused on formulation and delivery innovation. Incumbent players leverage broad distribution networks and clinician relationships to maintain a presence in hospital and retail channels, while specialized companies differentiate through novel extended-release technologies, transdermal systems, and product support services that simplify perioperative workflows.

Strategic activity centers on demonstrating clinical differentiation, securing favorable formulary positions within hospital systems, and forging partnerships with veterinary chains and online distributors. Additionally, companies that invest in robust post-market safety surveillance and targeted clinician education tend to gain trust among practitioners who prioritize predictable risk-benefit profiles. New entrants and smaller specialists often adopt nimble go-to-market approaches, using focused clinical pilots, key opinion leader engagement, and digital education platforms to accelerate adoption.

Collaborative models are increasingly common, with licensing, co-promotion, and distribution agreements enabling faster market access across regions with divergent regulatory hurdles. As commercialization becomes more channel-specific, companies that align product design with end-user preferences-such as favoring injectable extended-release formulations for specialty hospitals or convenient oral regimens for general practices-are better positioned to capture clinical mindshare and long-term loyalty.

Practical strategic moves for manufacturers and distributors to align evidence generation, formulation design, supply resilience, and channel engagement to gain competitive advantage

Industry leaders should adopt a coherent, evidence-driven strategy that aligns product innovation with clinical protocols and channel realities to secure sustainable advantage. First, prioritize multimodal clinical evidence generation that demonstrates how combinations of local anesthetics, NSAIDs, and selective opioid use improve patient outcomes and reduce complication rates. High-quality, practice-embedded trials and real-world data capture will strengthen value propositions for hospitals and clinics while supporting responsible stewardship narratives.

Second, align formulation strategy with end-user workflows by offering extended-release and transdermal options where they reduce dosing burden and improve compliance, and by ensuring injectable profiles support efficient perioperative use. Tailoring packaging, labeling, and educational materials to the needs of general practices versus specialty hospitals will improve uptake and reduce friction at the point of care. Third, develop resilient supply-chain models that account for tariff risk, favor diversified sourcing, and include contingency inventory strategies to maintain continuity of supply during global disruptions.

Fourth, invest in channel-specific commercial models that balance online pharmacy engagement with deep clinical partnerships. Digital education, telemedicine-aligned prescribing support, and clinic-facing decision aids can enhance appropriate product use. Finally, incorporate robust pharmacovigilance and opioid stewardship programs to meet regulatory expectations and build practitioner trust. Together, these measures will enable companies to convert clinical credibility into durable commercial performance while responsibly advancing patient care.

A robust mixed-methods research approach integrating clinician interviews, literature synthesis, and segmentation-driven scenario analysis to validate sector insights

The research underpinning this executive summary combines multiple qualitative and quantitative approaches to ensure a comprehensive understanding of clinical, commercial, and regulatory dynamics. Primary research included structured interviews with veterinary surgeons, general practitioners, formulary managers, and distribution executives to capture real-world prescribing behaviors, channel preferences, and operational constraints. Secondary research encompassed a cross-section of peer-reviewed veterinary clinical literature, regulatory guidance documents, and publicly available formulation and pharmacovigilance reports to contextualize product-level considerations and safety profiles.

Analytical techniques included cross-segmentation synthesis to map how product types, animal species, administration routes, and end-user channels interact, as well as scenario analysis to evaluate supply-chain disruptions and tariff impacts. Validation workshops with practicing clinicians and commercial stakeholders were used to test hypotheses and refine implications for product positioning and go-to-market tactics. Throughout the methodology, emphasis was placed on triangulating insights across multiple data sources to reduce single-source bias and to ensure relevance across diverse regional contexts.

A concise synthesis of convergence between clinical innovation, regulatory expectations, and commercial execution that outlines strategic priorities for the future

Postoperative pain management for companion animals is at an inflection point where clinical best practices, formulation advances, and shifting commercial channels converge to create new opportunities and obligations for stakeholders. The move toward multimodal analgesia, coupled with innovations in extended-release local anesthetics and transdermal delivery systems, enhances the capacity to deliver effective, owner-friendly pain control. At the same time, regulatory emphasis on opioid stewardship and evolving tariff landscapes demand more sophisticated supply-chain and clinical governance approaches.

Successfully navigating this landscape requires integrating rigorous clinical evidence with channel-aware commercialization and resilient sourcing strategies. Companies that invest in clinician engagement, differentiated formulations that solve practical problems, and robust pharmacovigilance frameworks will be better positioned to influence prescribing behavior and to achieve longer-term adoption. In essence, the future of companion animal postoperative analgesia will reward organizations that pair clinical credibility with operational excellence and a clear focus on practitioner and pet-owner needs.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Companion Animal Postoperative Pain Management Therapeutics Market, by Product Type

  • 8.1. Local Anesthetics
    • 8.1.1. Bupivacaine
    • 8.1.2. Lidocaine
  • 8.2. Non-Steroidal Anti-Inflammatory Drugs
    • 8.2.1. Carprofen
    • 8.2.2. Deracoxib
    • 8.2.3. Firocoxib
    • 8.2.4. Meloxicam
  • 8.3. Opioids
    • 8.3.1. Buprenorphine
    • 8.3.2. Fentanyl
    • 8.3.3. Tramadol

9. Companion Animal Postoperative Pain Management Therapeutics Market, by Animal Type

  • 9.1. Cats
  • 9.2. Dogs

10. Companion Animal Postoperative Pain Management Therapeutics Market, by Route Of Administration

  • 10.1. Injectable
  • 10.2. Oral
  • 10.3. Topical
  • 10.4. Transdermal Patch

11. Companion Animal Postoperative Pain Management Therapeutics Market, by End User

  • 11.1. Online Pharmacies
  • 11.2. Veterinary Hospitals And Clinics
    • 11.2.1. General Practices
    • 11.2.2. Specialty Hospitals
  • 11.3. Veterinary Retail Pharmacies
    • 11.3.1. Chain Pharmacies
    • 11.3.2. Independent Pharmacies

12. Companion Animal Postoperative Pain Management Therapeutics Market, by Region

  • 12.1. Americas
    • 12.1.1. North America
    • 12.1.2. Latin America
  • 12.2. Europe, Middle East & Africa
    • 12.2.1. Europe
    • 12.2.2. Middle East
    • 12.2.3. Africa
  • 12.3. Asia-Pacific

13. Companion Animal Postoperative Pain Management Therapeutics Market, by Group

  • 13.1. ASEAN
  • 13.2. GCC
  • 13.3. European Union
  • 13.4. BRICS
  • 13.5. G7
  • 13.6. NATO

14. Companion Animal Postoperative Pain Management Therapeutics Market, by Country

  • 14.1. United States
  • 14.2. Canada
  • 14.3. Mexico
  • 14.4. Brazil
  • 14.5. United Kingdom
  • 14.6. Germany
  • 14.7. France
  • 14.8. Russia
  • 14.9. Italy
  • 14.10. Spain
  • 14.11. China
  • 14.12. India
  • 14.13. Japan
  • 14.14. Australia
  • 14.15. South Korea

15. United States Companion Animal Postoperative Pain Management Therapeutics Market

16. China Companion Animal Postoperative Pain Management Therapeutics Market

17. Competitive Landscape

  • 17.1. Market Concentration Analysis, 2025
    • 17.1.1. Concentration Ratio (CR)
    • 17.1.2. Herfindahl Hirschman Index (HHI)
  • 17.2. Recent Developments & Impact Analysis, 2025
  • 17.3. Product Portfolio Analysis, 2025
  • 17.4. Benchmarking Analysis, 2025
  • 17.5. Addison Biological Laboratory Inc.
  • 17.6. Assisi Animal Health
  • 17.7. Avazzia
  • 17.8. Bayer AG
  • 17.9. Bimeda Animal Health
  • 17.10. Boehringer Ingelheim International GmbH
  • 17.11. Cadila Healthcare Ltd.
  • 17.12. Ceva Sante Animale
  • 17.13. Chanelle Pharma Group
  • 17.14. Daiichi Sankyo Co. Ltd.
  • 17.15. Dechra Pharmaceuticals PLC
  • 17.16. Elanco Animal Health Incorporated
  • 17.17. Eltech K-Laser SRL
  • 17.18. Fidelis Pharmaceuticals, LLC
  • 17.19. Merck & Co.
  • 17.20. Multi Radiance Medical
  • 17.21. Norbrook Laboratories
  • 17.22. Richter Pharma AG
  • 17.23. SAVA Vet
  • 17.24. Sequent Scientific Ltd.
  • 17.25. VETINDIA Pharmaceuticals Limited
  • 17.26. Vetoquinol S.A.
  • 17.27. Virbac Group
  • 17.28. Virpax Pharmaceuticals Inc.
  • 17.29. Zoetis Inc.

LIST OF FIGURES

  • FIGURE 1. GLOBAL COMPANION ANIMAL POSTOPERATIVE PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL COMPANION ANIMAL POSTOPERATIVE PAIN MANAGEMENT THERAPEUTICS MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL COMPANION ANIMAL POSTOPERATIVE PAIN MANAGEMENT THERAPEUTICS MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL COMPANION ANIMAL POSTOPERATIVE PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY PRODUCT TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL COMPANION ANIMAL POSTOPERATIVE PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY ANIMAL TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL COMPANION ANIMAL POSTOPERATIVE PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL COMPANION ANIMAL POSTOPERATIVE PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL COMPANION ANIMAL POSTOPERATIVE PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL COMPANION ANIMAL POSTOPERATIVE PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL COMPANION ANIMAL POSTOPERATIVE PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. UNITED STATES COMPANION ANIMAL POSTOPERATIVE PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 12. CHINA COMPANION ANIMAL POSTOPERATIVE PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL COMPANION ANIMAL POSTOPERATIVE PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL COMPANION ANIMAL POSTOPERATIVE PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL COMPANION ANIMAL POSTOPERATIVE PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY LOCAL ANESTHETICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL COMPANION ANIMAL POSTOPERATIVE PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY LOCAL ANESTHETICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL COMPANION ANIMAL POSTOPERATIVE PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY LOCAL ANESTHETICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL COMPANION ANIMAL POSTOPERATIVE PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY LOCAL ANESTHETICS, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL COMPANION ANIMAL POSTOPERATIVE PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY BUPIVACAINE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL COMPANION ANIMAL POSTOPERATIVE PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY BUPIVACAINE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL COMPANION ANIMAL POSTOPERATIVE PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY BUPIVACAINE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL COMPANION ANIMAL POSTOPERATIVE PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY LIDOCAINE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL COMPANION ANIMAL POSTOPERATIVE PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY LIDOCAINE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL COMPANION ANIMAL POSTOPERATIVE PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY LIDOCAINE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL COMPANION ANIMAL POSTOPERATIVE PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY NON-STEROIDAL ANTI-INFLAMMATORY DRUGS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL COMPANION ANIMAL POSTOPERATIVE PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY NON-STEROIDAL ANTI-INFLAMMATORY DRUGS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL COMPANION ANIMAL POSTOPERATIVE PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY NON-STEROIDAL ANTI-INFLAMMATORY DRUGS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL COMPANION ANIMAL POSTOPERATIVE PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY NON-STEROIDAL ANTI-INFLAMMATORY DRUGS, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL COMPANION ANIMAL POSTOPERATIVE PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY CARPROFEN, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL COMPANION ANIMAL POSTOPERATIVE PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY CARPROFEN, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL COMPANION ANIMAL POSTOPERATIVE PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY CARPROFEN, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL COMPANION ANIMAL POSTOPERATIVE PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY DERACOXIB, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL COMPANION ANIMAL POSTOPERATIVE PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY DERACOXIB, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL COMPANION ANIMAL POSTOPERATIVE PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY DERACOXIB, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL COMPANION ANIMAL POSTOPERATIVE PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY FIROCOXIB, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL COMPANION ANIMAL POSTOPERATIVE PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY FIROCOXIB, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL COMPANION ANIMAL POSTOPERATIVE PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY FIROCOXIB, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL COMPANION ANIMAL POSTOPERATIVE PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY MELOXICAM, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL COMPANION ANIMAL POSTOPERATIVE PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY MELOXICAM, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL COMPANION ANIMAL POSTOPERATIVE PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY MELOXICAM, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL COMPANION ANIMAL POSTOPERATIVE PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY OPIOIDS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL COMPANION ANIMAL POSTOPERATIVE PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY OPIOIDS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL COMPANION ANIMAL POSTOPERATIVE PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY OPIOIDS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL COMPANION ANIMAL POSTOPERATIVE PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY OPIOIDS, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL COMPANION ANIMAL POSTOPERATIVE PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY BUPRENORPHINE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL COMPANION ANIMAL POSTOPERATIVE PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY BUPRENORPHINE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL COMPANION ANIMAL POSTOPERATIVE PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY BUPRENORPHINE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL COMPANION ANIMAL POSTOPERATIVE PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY FENTANYL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL COMPANION ANIMAL POSTOPERATIVE PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY FENTANYL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL COMPANION ANIMAL POSTOPERATIVE PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY FENTANYL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL COMPANION ANIMAL POSTOPERATIVE PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY TRAMADOL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL COMPANION ANIMAL POSTOPERATIVE PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY TRAMADOL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL COMPANION ANIMAL POSTOPERATIVE PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY TRAMADOL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL COMPANION ANIMAL POSTOPERATIVE PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY ANIMAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL COMPANION ANIMAL POSTOPERATIVE PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY CATS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL COMPANION ANIMAL POSTOPERATIVE PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY CATS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL COMPANION ANIMAL POSTOPERATIVE PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY CATS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL COMPANION ANIMAL POSTOPERATIVE PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY DOGS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL COMPANION ANIMAL POSTOPERATIVE PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY DOGS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL COMPANION ANIMAL POSTOPERATIVE PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY DOGS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL COMPANION ANIMAL POSTOPERATIVE PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL COMPANION ANIMAL POSTOPERATIVE PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY INJECTABLE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL COMPANION ANIMAL POSTOPERATIVE PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY INJECTABLE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL COMPANION ANIMAL POSTOPERATIVE PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY INJECTABLE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL COMPANION ANIMAL POSTOPERATIVE PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY ORAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL COMPANION ANIMAL POSTOPERATIVE PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY ORAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL COMPANION ANIMAL POSTOPERATIVE PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY ORAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL COMPANION ANIMAL POSTOPERATIVE PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY TOPICAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL COMPANION ANIMAL POSTOPERATIVE PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY TOPICAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL COMPANION ANIMAL POSTOPERATIVE PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY TOPICAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL COMPANION ANIMAL POSTOPERATIVE PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY TRANSDERMAL PATCH, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL COMPANION ANIMAL POSTOPERATIVE PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY TRANSDERMAL PATCH, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL COMPANION ANIMAL POSTOPERATIVE PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY TRANSDERMAL PATCH, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL COMPANION ANIMAL POSTOPERATIVE PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL COMPANION ANIMAL POSTOPERATIVE PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL COMPANION ANIMAL POSTOPERATIVE PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY ONLINE PHARMACIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL COMPANION ANIMAL POSTOPERATIVE PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY ONLINE PHARMACIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL COMPANION ANIMAL POSTOPERATIVE PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY VETERINARY HOSPITALS AND CLINICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL COMPANION ANIMAL POSTOPERATIVE PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY VETERINARY HOSPITALS AND CLINICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL COMPANION ANIMAL POSTOPERATIVE PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY VETERINARY HOSPITALS AND CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL COMPANION ANIMAL POSTOPERATIVE PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY VETERINARY HOSPITALS AND CLINICS, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL COMPANION ANIMAL POSTOPERATIVE PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY GENERAL PRACTICES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL COMPANION ANIMAL POSTOPERATIVE PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY GENERAL PRACTICES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL COMPANION ANIMAL POSTOPERATIVE PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY GENERAL PRACTICES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL COMPANION ANIMAL POSTOPERATIVE PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY SPECIALTY HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL COMPANION ANIMAL POSTOPERATIVE PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY SPECIALTY HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL COMPANION ANIMAL POSTOPERATIVE PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY SPECIALTY HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL COMPANION ANIMAL POSTOPERATIVE PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY VETERINARY RETAIL PHARMACIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL COMPANION ANIMAL POSTOPERATIVE PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY VETERINARY RETAIL PHARMACIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL COMPANION ANIMAL POSTOPERATIVE PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY VETERINARY RETAIL PHARMACIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL COMPANION ANIMAL POSTOPERATIVE PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY VETERINARY RETAIL PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL COMPANION ANIMAL POSTOPERATIVE PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY CHAIN PHARMACIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL COMPANION ANIMAL POSTOPERATIVE PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY CHAIN PHARMACIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 82. GLOBAL COMPANION ANIMAL POSTOPERATIVE PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY CHAIN PHARMACIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 83. GLOBAL COMPANION ANIMAL POSTOPERATIVE PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY INDEPENDENT PHARMACIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 84. GLOBAL COMPANION ANIMAL POSTOPERATIVE PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY INDEPENDENT PHARMACIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 85. GLOBAL COMPANION ANIMAL POSTOPERATIVE PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY INDEPENDENT PHARMACIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 86. GLOBAL COMPANION ANIMAL POSTOPERATIVE PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 87. AMERICAS COMPANION ANIMAL POSTOPERATIVE PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 88. AMERICAS COMPANION ANIMAL POSTOPERATIVE PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 89. AMERICAS COMPANION ANIMAL POSTOPERATIVE PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY LOCAL ANESTHETICS, 2018-2032 (USD MILLION)
  • TABLE 90. AMERICAS COMPANION ANIMAL POSTOPERATIVE PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY NON-STEROIDAL ANTI-INFLAMMATORY DRUGS, 2018-2032 (USD MILLION)
  • TABLE 91. AMERICAS COMPANION ANIMAL POSTOPERATIVE PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY OPIOIDS, 2018-2032 (USD MILLION)
  • TABLE 92. AMERICAS COMPANION ANIMAL POSTOPERATIVE PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY ANIMAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 93. AMERICAS COMPANION ANIMAL POSTOPERATIVE PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 94. AMERICAS COMPANION ANIMAL POSTOPERATIVE PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 95. AMERICAS COMPANION ANIMAL POSTOPERATIVE PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY VETERINARY HOSPITALS AND CLINICS, 2018-2032 (USD MILLION)
  • TABLE 96. AMERICAS COMPANION ANIMAL POSTOPERATIVE PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY VETERINARY RETAIL PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 97. NORTH AMERICA COMPANION ANIMAL POSTOPERATIVE PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 98. NORTH AMERICA COMPANION ANIMAL POSTOPERATIVE PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 99. NORTH AMERICA COMPANION ANIMAL POSTOPERATIVE PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY LOCAL ANESTHETICS, 2018-2032 (USD MILLION)
  • TABLE 100. NORTH AMERICA COMPANION ANIMAL POSTOPERATIVE PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY NON-STEROIDAL ANTI-INFLAMMATORY DRUGS, 2018-2032 (USD MILLION)
  • TABLE 101. NORTH AMERICA COMPANION ANIMAL POSTOPERATIVE PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY OPIOIDS, 2018-2032 (USD MILLION)
  • TABLE 102. NORTH AMERICA COMPANION ANIMAL POSTOPERATIVE PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY ANIMAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 103. NORTH AMERICA COMPANION ANIMAL POSTOPERATIVE PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 104. NORTH AMERICA COMPANION ANIMAL POSTOPERATIVE PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 105. NORTH AMERICA COMPANION ANIMAL POSTOPERATIVE PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY VETERINARY HOSPITALS AND CLINICS, 2018-2032 (USD MILLION)
  • TABLE 106. NORTH AMERICA COMPANION ANIMAL POSTOPERATIVE PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY VETERINARY RETAIL PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 107. LATIN AMERICA COMPANION ANIMAL POSTOPERATIVE PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 108. LATIN AMERICA COMPANION ANIMAL POSTOPERATIVE PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 109. LATIN AMERICA COMPANION ANIMAL POSTOPERATIVE PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY LOCAL ANESTHETICS, 2018-2032 (USD MILLION)
  • TABLE 110. LATIN AMERICA COMPANION ANIMAL POSTOPERATIVE PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY NON-STEROIDAL ANTI-INFLAMMATORY DRUGS, 2018-2032 (USD MILLION)
  • TABLE 111. LATIN AMERICA COMPANION ANIMAL POSTOPERATIVE PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY OPIOIDS, 2018-2032 (USD MILLION)
  • TABLE 112. LATIN AMERICA COMPANION ANIMAL POSTOPERATIVE PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY ANIMAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 113. LATIN AMERICA COMPANION ANIMAL POSTOPERATIVE PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 114. LATIN AMERICA COMPANION ANIMAL POSTOPERATIVE PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 115. LATIN AMERICA COMPANION ANIMAL POSTOPERATIVE PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY VETERINARY HOSPITALS AND CLINICS, 2018-2032 (USD MILLION)
  • TABLE 116. LATIN AMERICA COMPANION ANIMAL POSTOPERATIVE PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY VETERINARY RETAIL PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 117. EUROPE, MIDDLE EAST & AFRICA COMPANION ANIMAL POSTOPERATIVE PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 118. EUROPE, MIDDLE EAST & AFRICA COMPANION ANIMAL POSTOPERATIVE PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 119. EUROPE, MIDDLE EAST & AFRICA COMPANION ANIMAL POSTOPERATIVE PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY LOCAL ANESTHETICS, 2018-2032 (USD MILLION)
  • TABLE 120. EUROPE, MIDDLE EAST & AFRICA COMPANION ANIMAL POSTOPERATIVE PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY NON-STEROIDAL ANTI-INFLAMMATORY DRUGS, 2018-2032 (USD MILLION)
  • TABLE 121. EUROPE, MIDDLE EAST & AFRICA COMPANION ANIMAL POSTOPERATIVE PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY OPIOIDS, 2018-2032 (USD MILLION)
  • TABLE 122. EUROPE, MIDDLE EAST & AFRICA COMPANION ANIMAL POSTOPERATIVE PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY ANIMAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 123. EUROPE, MIDDLE EAST & AFRICA COMPANION ANIMAL POSTOPERATIVE PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 124. EUROPE, MIDDLE EAST & AFRICA COMPANION ANIMAL POSTOPERATIVE PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 125. EUROPE, MIDDLE EAST & AFRICA COMPANION ANIMAL POSTOPERATIVE PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY VETERINARY HOSPITALS AND CLINICS, 2018-2032 (USD MILLION)
  • TABLE 126. EUROPE, MIDDLE EAST & AFRICA COMPANION ANIMAL POSTOPERATIVE PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY VETERINARY RETAIL PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 127. EUROPE COMPANION ANIMAL POSTOPERATIVE PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 128. EUROPE COMPANION ANIMAL POSTOPERATIVE PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 129. EUROPE COMPANION ANIMAL POSTOPERATIVE PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY LOCAL ANESTHETICS, 2018-2032 (USD MILLION)
  • TABLE 130. EUROPE COMPANION ANIMAL POSTOPERATIVE PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY NON-STEROIDAL ANTI-INFLAMMATORY DRUGS, 2018-2032 (USD MILLION)
  • TABLE 131. EUROPE COMPANION ANIMAL POSTOPERATIVE PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY OPIOIDS, 2018-2032 (USD MILLION)
  • TABLE 132. EUROPE COMPANION ANIMAL POSTOPERATIVE PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY ANIMAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 133. EUROPE COMPANION ANIMAL POSTOPERATIVE PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 134. EUROPE COMPANION ANIMAL POSTOPERATIVE PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 135. EUROPE COMPANION ANIMAL POSTOPERATIVE PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY VETERINARY HOSPITALS AND CLINICS, 2018-2032 (USD MILLION)
  • TABLE 136. EUROPE COMPANION ANIMAL POSTOPERATIVE PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY VETERINARY RETAIL PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 137. MIDDLE EAST COMPANION ANIMAL POSTOPERATIVE PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 138. MIDDLE EAST COMPANION ANIMAL POSTOPERATIVE PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 139. MIDDLE EAST COMPANION ANIMAL POSTOPERATIVE PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY LOCAL ANESTHETICS, 2018-2032 (USD MILLION)
  • TABLE 140. MIDDLE EAST COMPANION ANIMAL POSTOPERATIVE PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY NON-STEROIDAL ANTI-INFLAMMATORY DRUGS, 2018-2032 (USD MILLION)
  • TABLE 141. MIDDLE EAST COMPANION ANIMAL POSTOPERATIVE PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY OPIOIDS, 2018-2032 (USD MILLION)
  • TABLE 142. MIDDLE EAST COMPANION ANIMAL POSTOPERATIVE PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY ANIMAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 143. MIDDLE EAST COMPANION ANIMAL POSTOPERATIVE PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 144. MIDDLE EAST COMPANION ANIMAL POSTOPERATIVE PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 145. MIDDLE EAST COMPANION ANIMAL POSTOPERATIVE PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY VETERINARY HOSPITALS AND CLINICS, 2018-2032 (USD MILLION)
  • TABLE 146. MIDDLE EAST COMPANION ANIMAL POSTOPERATIVE PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY VETERINARY RETAIL PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 147. AFRICA COMPANION ANIMAL POSTOPERATIVE PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 148. AFRICA COMPANION ANIMAL POSTOPERATIVE PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 149. AFRICA COMPANION ANIMAL POSTOPERATIVE PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY LOCAL ANESTHETICS, 2018-2032 (USD MILLION)
  • TABLE 150. AFRICA COMPANION ANIMAL POSTOPERATIVE PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY NON-STEROIDAL ANTI-INFLAMMATORY DRUGS, 2018-2032 (USD MILLION)
  • TABLE 151. AFRICA COMPANION ANIMAL POSTOPERATIVE PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY OPIOIDS, 2018-2032 (USD MILLION)
  • TABLE 152. AFRICA COMPANION ANIMAL POSTOPERATIVE PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY ANIMAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 153. AFRICA COMPANION ANIMAL POSTOPERATIVE PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 154. AFRICA COMPANION ANIMAL POSTOPERATIVE PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 155. AFRICA COMPANION ANIMAL POSTOPERATIVE PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY VETERINARY HOSPITALS AND CLINICS, 2018-2032 (USD MILLION)
  • TABLE 156. AFRICA COMPANION ANIMAL POSTOPERATIVE PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY VETERINARY RETAIL PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 157. ASIA-PACIFIC COMPANION ANIMAL POSTOPERATIVE PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 158. ASIA-PACIFIC COMPANION ANIMAL POSTOPERATIVE PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 159. ASIA-PACIFIC COMPANION ANIMAL POSTOPERATIVE PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY LOCAL ANESTHETICS, 2018-2032 (USD MILLION)
  • TABLE 160. ASIA-PACIFIC COMPANION ANIMAL POSTOPERATIVE PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY NON-STEROIDAL ANTI-INFLAMMATORY DRUGS, 2018-2032 (USD MILLION)
  • TABLE 161. ASIA-PACIFIC COMPANION ANIMAL POSTOPERATIVE PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY OPIOIDS, 2018-2032 (USD MILLION)
  • TABLE 162. ASIA-PACIFIC COMPANION ANIMAL POSTOPERATIVE PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY ANIMAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 163. ASIA-PACIFIC COMPANION ANIMAL POSTOPERATIVE PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 164. ASIA-PACIFIC COMPANION ANIMAL POSTOPERATIVE PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 165. ASIA-PACIFIC COMPANION ANIMAL POSTOPERATIVE PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY VETERINARY HOSPITALS AND CLINICS, 2018-2032 (USD MILLION)
  • TABLE 166. ASIA-PACIFIC COMPANION ANIMAL POSTOPERATIVE PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY VETERINARY RETAIL PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 167. GLOBAL COMPANION ANIMAL POSTOPERATIVE PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 168. ASEAN COMPANION ANIMAL POSTOPERATIVE PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 169. ASEAN COMPANION ANIMAL POSTOPERATIVE PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 170. ASEAN COMPANION ANIMAL POSTOPERATIVE PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY LOCAL ANESTHETICS, 2018-2032 (USD MILLION)
  • TABLE 171. ASEAN COMPANION ANIMAL POSTOPERATIVE PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY NON-STEROIDAL ANTI-INFLAMMATORY DRUGS, 2018-2032 (USD MILLION)
  • TABLE 172. ASEAN COMPANION ANIMAL POSTOPERATIVE PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY OPIOIDS, 2018-2032 (USD MILLION)
  • TABLE 173. ASEAN COMPANION ANIMAL POSTOPERATIVE PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY ANIMAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 174. ASEAN COMPANION ANIMAL POSTOPERATIVE PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 175. ASEAN COMPANION ANIMAL POSTOPERATIVE PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 176. ASEAN COMPANION ANIMAL POSTOPERATIVE PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY VETERINARY HOSPITALS AND CLINICS, 2018-2032 (USD MILLION)
  • TABLE 177. ASEAN COMPANION ANIMAL POSTOPERATIVE PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY VETERINARY RETAIL PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 178. GCC COMPANION ANIMAL POSTOPERATIVE PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 179. GCC COMPANION ANIMAL POSTOPERATIVE PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 180. GCC COMPANION ANIMAL POSTOPERATIVE PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY LOCAL ANESTHETICS, 2018-2032 (USD MILLION)
  • TABLE 181. GCC COMPANION ANIMAL POSTOPERATIVE PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY NON-STEROIDAL ANTI-INFLAMMATORY DRUGS, 2018-2032 (USD MILLION)
  • TABLE 182. GCC COMPANION ANIMAL POSTOPERATIVE PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY OPIOIDS, 2018-2032 (USD MILLION)
  • TABLE 183. GCC COMPANION ANIMAL POSTOPERATIVE PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY ANIMAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 184. GCC COMPANION ANIMAL POSTOPERATIVE PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 185. GCC COMPANION ANIMAL POSTOPERATIVE PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 186. GCC COMPANION ANIMAL POSTOPERATIVE PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY VETERINARY HOSPITALS AND CLINICS, 2018-2032 (USD MILLION)
  • TABLE 187. GCC COMPANION ANIMAL POSTOPERATIVE PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY VETERINARY RETAIL PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 188. EUROPEAN UNION COMPANION ANIMAL POSTOPERATIVE PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 189. EUROPEAN UNION COMPANION ANIMAL POSTOPERATIVE PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 190. EUROPEAN UNION COMPANION ANIMAL POSTOPERATIVE PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY LOCAL ANESTHETICS, 2018-2032 (USD MILLION)
  • TABLE 191. EUROPEAN UNION COMPANION ANIMAL POSTOPERATIVE PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY NON-STEROIDAL ANTI-INFLAMMATORY DRUGS, 2018-2032 (USD MILLION)
  • TABLE 192. EUROPEAN UNION COMPANION ANIMAL POSTOPERATIVE PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY OPIOIDS, 2018-2032 (USD MILLION)
  • TABLE 193. EUROPEAN UNION COMPANION ANIMAL POSTOPERATIVE PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY ANIMAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 194. EUROPEAN UNION COMPANION ANIMAL POSTOPERATIVE PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 195. EUROPEAN UNION COMPANION ANIMAL POSTOPERATIVE PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 196. EUROPEAN UNION COMPANION ANIMAL POSTOPERATIVE PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY VETERINARY HOSPITALS AND CLINICS, 2018-2032 (USD MILLION)
  • TABLE 197. EUROPEAN UNION COMPANION ANIMAL POSTOPERATIVE PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY VETERINARY RETAIL PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 198. BRICS COMPANION ANIMAL POSTOPERATIVE PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 199. BRICS COMPANION ANIMAL POSTOPERATIVE PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 200. BRICS COMPANION ANIMAL POSTOPERATIVE PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY LOCAL ANESTHETICS, 2018-2032 (USD MILLION)
  • TABLE 201. BRICS COMPANION ANIMAL POSTOPERATIVE PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY NON-STEROIDAL ANTI-INFLAMMATORY DRUGS, 2018-2032 (USD MILLION)
  • TABLE 202. BRICS COMPANION ANIMAL POSTOPERATIVE PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY OPIOIDS, 2018-2032 (USD MILLION)
  • TABLE 203. BRICS COMPANION ANIMAL POSTOPERATIVE PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY ANIMAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 204. BRICS COMPANION ANIMAL POSTOPERATIVE PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 205. BRICS COMPANION ANIMAL POSTOPERATIVE PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 206. BRICS COMPANION ANIMAL POSTOPERATIVE PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY VETERINARY HOSPITALS AND CLINICS, 2018-2032 (USD MILLION)
  • TABLE 207. BRICS COMPANION ANIMAL POSTOPERATIVE PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY VETERINARY RETAIL PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 208. G7 COMPANION ANIMAL POSTOPERATIVE PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 209. G7 COMPANION ANIMAL POSTOPERATIVE PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 210. G7 COMPANION ANIMAL POSTOPERATIVE PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY LOCAL ANESTHETICS, 2018-2032 (USD MILLION)
  • TABLE 211. G7 COMPANION ANIMAL POSTOPERATIVE PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY NON-STEROIDAL ANTI-INFLAMMATORY DRUGS, 2018-2032 (USD MILLION)
  • TABLE 212. G7 COMPANION ANIMAL POSTOPERATIVE PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY OPIOIDS, 2018-2032 (USD MILLION)
  • TABLE 213. G7 COMPANION ANIMAL POSTOPERATIVE PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY ANIMAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 214. G7 COMPANION ANIMAL POSTOPERATIVE PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 215. G7 COMPANION ANIMAL POSTOPERATIVE PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 216. G7 COMPANION ANIMAL POSTOPERATIVE PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY VETERINARY HOSPITALS AND CLINICS, 2018-2032 (USD MILLION)
  • TABLE 217. G7 COMPANION ANIMAL POSTOPERATIVE PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY VETERINARY RETAIL PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 218. NATO COMPANION ANIMAL POSTOPERATIVE PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 219. NATO COMPANION ANIMAL POSTOPERATIVE PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 220. NATO COMPANION ANIMAL POSTOPERATIVE PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY LOCAL ANESTHETICS, 2018-2032 (USD MILLION)
  • TABLE 221. NATO COMPANION ANIMAL POSTOPERATIVE PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY NON-STEROIDAL ANTI-INFLAMMATORY DRUGS, 2018-2032 (USD MILLION)
  • TABLE 222. NATO COMPANION ANIMAL POSTOPERATIVE PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY OPIOIDS, 2018-2032 (USD MILLION)
  • TABLE 223. NATO COMPANION ANIMAL POSTOPERATIVE PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY ANIMAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 224. NATO COMPANION ANIMAL POSTOPERATIVE PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 225. NATO COMPANION ANIMAL POSTOPERATIVE PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 226. NATO COMPANION ANIMAL POSTOPERATIVE PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY VETERINARY HOSPITALS AND CLINICS, 2018-2032 (USD MILLION)
  • TABLE 227. NATO COMPANION ANIMAL POSTOPERATIVE PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY VETERINARY RETAIL PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 228. GLOBAL COMPANION ANIMAL POSTOPERATIVE PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 229. UNITED STATES COMPANION ANIMAL POSTOPERATIVE PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 230. UNITED STATES COMPANION ANIMAL POSTOPERATIVE PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 231. UNITED STATES COMPANION ANIMAL POSTOPERATIVE PAIN MANAGEMENT THERAPEUTICS MARKET SIZE, BY LOCAL ANESTHETICS, 2018-2032 (USD MILLION)
  • TABLE 232. UNITED STATES COMPANION ANIMAL POSTOPERATIV